ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages

Genetic variation around the LRRK2 gene affects risk for both familial and sporadic Parkinson’s disease (PD). LRRK2 levels have become an appealing target for potential PD therapeutics with LRRK2 antisense oligonucleotides (ASOs) now moving toward clinical trials. However, LRRK2 has been suggested t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallings, Rebecca L., Mark, Julian R., Staley, Hannah A., Gillett, Drew A., Neighbarger, Noelle, Kordasiewicz, Holly, Hirst, Warren D., Tansey, Malú Gámez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661462/
https://www.ncbi.nlm.nih.gov/pubmed/38028198
http://dx.doi.org/10.1016/j.omtn.2023.102064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661462/
https://www.ncbi.nlm.nih.gov/pubmed/38028198
http://dx.doi.org/10.1016/j.omtn.2023.102064

Ejemplares similares